Drug
Axs 05
Axs 05: highest development phase Post-Market, developed by Axsome Therapeutics. 10 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Axsome Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| AXS-05 NCT06223880 | Post-Market | Major Depressive Disorder |
| AXS-05 NCT05557409 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type |
| AXS-05 NCT04797715 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type |
| AXS-05 (dextromethorphan and bupropion) oral tablets NCT04039022 | Phase 3 | Major Depressive Disorder |
| AXS-05 (dextromethorphan-bupropion) NCT06736509 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type |
| AXS-05 (dextromethorphan-bupropion) NCT07766655 | Phase 3 | Smoking Cessation |
| AXS-05 NCT03226522 | Phase 2/3 | Agitation in Patients With Dementia of the Alzheimer's Type |
| AXS-05 (dextromethorphan-bupropion) NCT04634669 | Phase 2 | Treatment Resistant Depression |
| AXS-05 NCT03595579 | Phase 2 | Major Depressive Disorder |
| AXS-05 NCT04608396 | Phase 2 | Treatment Resistant Depression |
Latest
No recent events.
Follow Axs 05 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.